Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2018-05-11 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-05-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes a Commercial Platform License Agreement entered into by Ligand Pharmaceuticals, including financial terms such as upfront payments and royalties. There are no financial statements or detailed financial analysis present, and the document is relatively short (3791 characters). It is not an earnings release or annual/interim report but rather an announcement of a material business event. Therefore, this fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings like 8-Ks that do not fit other specific categories.
2018-05-10 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2018, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2018. The text explicitly states that the press release is furnished as an exhibit and is a current report on Form 8-K. The document does not contain the full financial results or detailed financial statements but rather announces the release of such information. According to the rules, an 8-K filing announcing earnings results is classified as an Earnings Release (ER). The document length is 3019 characters, which is short and consistent with an earnings release announcement rather than a full report. Therefore, the appropriate classification is Earnings Release (ER).
2018-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is titled as a Definitive Additional Materials filing related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (1920 characters) and contains no financial data or detailed report content, but rather is a filing related to proxy solicitation. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2018-04-30 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.